Canaccord Genuity Maintains Buy on Ocugen, Lowers Price Target to $11

Benzinga Newsdesk www.benzinga.com Negative 70.6%

Neg 70.6% Neu 0% Pos 0%

Canaccord Genuity analyst Whitney Ijem maintains Ocugen (NASDAQ:OCGN) with a Buy and lowers the price target from $12 to $11.